Basel, Switzerland — September 22, 2025 — Positive phase III trial results from the evERA study reveal that the investigational therapy giredestrant combined with everolimus significantly improves progression-free survival (PFS) in patients with ER-positive, HER2-negative advanced breast cancer who had previously received a CDK4/6 inhibitor and endocrine therapy. The results highlight the promise of an all-oral regimen in a setting where treatment resistance remains a critical challenge.

Science Significance

The evERA trial demonstrated that giredestrant, an oral selective estrogen receptor degrader (SERD), combined with everolimus, achieved meaningful clinical benefit in both the intention-to-treat population and the ESR1-mutated subgroup. Importantly, no new safety signals were observed, and adverse events were consistent with known profiles, marking the first successful head-to-head phase III trial of an oral SERD regimen against standard endocrine care.

Regulatory Significance

These findings will be shared with global health authorities as discussions begin for potential regulatory approval. By demonstrating significant PFS improvements in a population with limited options, this regimen may satisfy requirements for accelerated review pathways. Regulatory bodies such as the FDA and EMA are expected to scrutinize outcomes in both primary and ESR1-mutated groups, which are increasingly recognized in clinical guidelines.

Business Significance

The evERA study strengthens the pipeline of innovative breast cancer therapies and signals major market opportunities in the post-CDK4/6 setting, an area of high unmet need. Introducing an all-oral combination could reduce treatment complexity, support better patient adherence, and create commercial differentiation against existing injectables, while diversifying the oncology portfolio with a first-in-class SERD-based strategy.

Patients’ Significance

For patients, the giredestrant combination offers hope of delaying progression, extending quality of life, and reducing the treatment burden through oral administration instead of injections. With breast cancer being the most common cancer among women globally, accounting for 2.3 million new cases annually, this therapeutic option could directly impact survival and everyday living for thousands of women worldwide.

Policy Significance

The trial underscores the importance of precision medicine and combination regimens in cancer care. Policymakers focused on oncology innovation may see this as justification for faster regulatory review frameworks, broader clinical trial access, and updated treatment guidelines for ER-positive breast cancer. Such advances also align with global health strategies targeting reductions in cancer mortality.

The evERA phase III results mark a milestone in breast cancer research, demonstrating that giredestrant plus everolimus could reshape treatment for ER-positive, HER2-negative advanced disease. As regulatory submissions move forward, this innovation highlights the growing role of oral SERD therapies in tackling resistant cancers and improving patient outcomes.

Source: Roche Press Release